Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
about
Multiple myeloma in the marrow: pathogenesis and treatments.TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.
P2860
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@ast
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@en
type
label
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@ast
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@en
prefLabel
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@ast
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@en
P2093
P2860
P1433
P1476
Combination of a Selective HSP ...... ity in Multiple Myeloma Cells.
@en
P2093
Dharminder Chauhan
Diana Cirstea
Francesca Cottini
Gullu Gorgun
Hiroto Ohguchi
Jana Jakubikova
Jiro Minami
Kiyoshi Ando
Morihiko Sagawa
Naoya Mimura
P2860
P304
P356
10.1371/JOURNAL.PONE.0143847
P407
P577
2015-12-02T00:00:00Z